Here we present a case report of a patient with prostate cancer in whom rebiopsy and WGS at the point of disease progression had a significant and ongoing clinical impact because of the identification of a tumoral BRCA2 deletion not present in the initial biopsy. This evidence concerns the gene BRCA2 and prostate cancer.